Israel's IceCure Medical said on Sunday it received U.S. regulatory approval to expand the use of its cryoablation technology to treat benign and cancerous tumors in livers and kidneys, sending its share price up 30%.
from Reuters: Health News https://ift.tt/2scXVZB
No comments:
Post a Comment